Poly adenosine diphosphate-ribosylation and neurodegenerative diseases.
- Author:
Yi WANG
1
;
Yunbi LU
1
Author Information
1. Department of Pharmacology, College of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou 310058, China.
- Publication Type:Journal Article
- MeSH:
ADP-Ribosylation;
Humans;
Neurodegenerative Diseases;
physiopathology;
Poly Adenosine Diphosphate Ribose;
Poly(ADP-ribose) Polymerases;
metabolism
- From:
Journal of Zhejiang University. Medical sciences
2020;49(1):100-106
- CountryChina
- Language:Chinese
-
Abstract:
The morbidity of neurodegenerative diseases are increased in recent years, however, the treatment is limited. Poly ADP-ribosylation (PARylation) is a post-translational modification of protein that catalyzed by poly(ADP-ribose) polymerase (PARP). Studies have shown that PARylation is involved in many neurodegenerative diseases such as stroke, Parkinson's diseases, Alzheimer's disease, amyotrophic lateral sclerosis and so on, by affecting intracellular translocation of protein molecules, protein aggregation, protein activity, and cell death. PARP inhibitors have showed neuroprotective efficacy for neurodegenerative diseases in pre-clinical studies and phase Ⅰ clinical trials. To find new PARP inhibitors with more specific effects and specific pharmacokinetic characteristics will be the new direction for the treatment of neurodegenerative diseases. This paper reviews the recent progress on PARylation in neurodegenerative diseases.
